165 related articles for article (PubMed ID: 22706966)
1. Novel agents in Hodgkin lymphoma.
Moskowitz AJ
Curr Oncol Rep; 2012 Oct; 14(5):419-23. PubMed ID: 22706966
[TBL] [Abstract][Full Text] [Related]
2. An update on emerging drugs for Hodgkin lymphoma.
von Tresckow B; Diehl V
Expert Opin Emerg Drugs; 2014 Jun; 19(2):215-24. PubMed ID: 24749769
[TBL] [Abstract][Full Text] [Related]
3. Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Ramchandren R
Oncologist; 2012; 17(3):367-76. PubMed ID: 22387318
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
Dougherty DW; Friedberg JW
Curr Hematol Malig Rep; 2010 Jul; 5(3):148-56. PubMed ID: 20437115
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
6. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
7. [Current development of new drugs in malignant lymphoma].
Ogura M
Nihon Rinsho; 2012 Apr; 70 Suppl 2():715-30. PubMed ID: 23134034
[No Abstract] [Full Text] [Related]
8. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
Eichenauer DA; Engert A
Expert Rev Hematol; 2017 Sep; 10(9):775-782. PubMed ID: 28665214
[TBL] [Abstract][Full Text] [Related]
9. [Hodgkin lymphoma].
Nagai H
Nihon Rinsho; 2014 Jun; 72(6):1099-103. PubMed ID: 25016811
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
14. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.
Friedberg JW; Forero-Torres A; Bordoni RE; Cline VJM; Patel Donnelly D; Flynn PJ; Olsen G; Chen R; Fong A; Wang Y; Yasenchak CA
Blood; 2017 Dec; 130(26):2829-2837. PubMed ID: 29038340
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.
Faulk KE; Sopfe JM; Campbell K; Liptzin DR; Liu AK; Franklin ARK; Cost CR
Br J Haematol; 2018 Oct; 183(2):251-256. PubMed ID: 30198571
[TBL] [Abstract][Full Text] [Related]
16. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Janku F; Park H; Call SG; Madwani K; Oki Y; Subbiah V; Hong DS; Naing A; Velez-Bravo VM; Barnes TG; Hagemeister FB; Falchook GS; Karp DD; Wheler JJ; Piha-Paul SA; Garrido-Laguna I; Shpall EJ; Fayad LE; Neelapu SS; Meric-Bernstam F; Kurzrock R; Fanale MA
Clin Cancer Res; 2020 Nov; 26(21):5579-5587. PubMed ID: 33055173
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.
Graf SA; Gopal AK
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):151-7. PubMed ID: 25696848
[TBL] [Abstract][Full Text] [Related]
19. [Effect of brentuximab vedotin combined with chlormethine hydrochloride on the treatment of 6 patients with relapsed and refractory Hodgkin lymphoma].
Cao Z; Wang Z; Sun J; Peng C; Feng S; Zhou X; Yang Q
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):575-7. PubMed ID: 26304081
[TBL] [Abstract][Full Text] [Related]
20. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]